Jay Olson
Managing Director Oppenheimer & Co.
Jay Olson is Managing Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Jay covered SMID-cap names and worked on the Large Cap Pharmaceuticals team at Goldman Sachs for 4 years after 4 years on the #1 II-ranked Large Cap Pharmaceuticals team at Sanford Bernstein. Prior to Wall Street, Jay spent 18 years in the pharmaceutical industry, working mostly for Pfizer in finance, marketing and business development. Jay received an MBA in Finance and an MS in Chemical Engineering both from MIT, and a BS in Chemical Engineering from Tufts University. He also holds the CFA designation.
Seminars
This highly interactive and extended workshop offers a deep dive into the GLP-1 landscape, moving beyond clinical data to focus squarely on market opportunity, investor perception, and financial strategy. Attendees will gain practical insights on the most promising “Future of GLP-1” opportunities – from multi-agonists to neurobiology and novel indications – and learn how to translate these scientific concepts into compelling, fundable, and profitable business plans that capture commercial interest. The session integrates real-time audience surveys, displaying live results to benchmark audience sentiment against expert opinion, ensuring maximum engagement and direct relevance.
This workshop will gather experts to discuss:
- Evaluating the true peak sales potential and valuation drivers for next-generation GLP- 1s, including the financial impact of expanding into key indications like MASH, CKD and beyond to neurological disorders and addiction
- Utilizing interactive audience polls to assess which next-frontier innovations (e.g., muscle preservation, oral formulation, neurobiology) investors are actively prioritizing for the next five years
- Analyzing recent M&A and licensing activity in the cardiometabolic space to project which asset types and company profiles are most likely to be acquisition targets and the specific metrics currently driving those deals
- Demonstrating how companies can weave complex GLP-1 mechanisms into an attractive and robust business plan that secures executive and investor buy-in
- Tailoring funding roadmaps and communication strategies to attract different pools of capital (Venture vs. Public Equity) while navigating the stringent non-clinical criteria of investor due diligence
